Expanding Industrial Materials and Global Markets through M&A
First written in FY2016. 23 of 29 entries say "Advanced", first in FY2016-Q2. Latest entry: FY2026-H1.
0 other companies' latest entry also says "Other".
- FY2026-H1Decision to transfer the interest after the acquisitionAnnual report
「On 20 May 2026, the Company acquired 60% of the shares of USM in Vietnam and made it a consolidated subsidiary. The purpose of the acquisition was to strengthen and improve the efficiency of USM's existing business and promote the geographic expansion of the Company's medical device CDMO operations in Southeast Asia.」
The Company sought to expand its medical device CDMO operations in Southeast Asia by acquiring 60% of USM and making it a subsidiary. Following the discovery of improper accounting treatment before the acquisition, it transferred 50% effective 17 September 2026 and planned to transfer the remaining 10%. - FY2025AdvancedAnnual report
「At a meeting of the Board of Directors held on 20 December 2024, the Company resolved to acquire the shares of 滋賀県製薬株式会社 (滋賀県製薬) and make it a subsidiary. It acquired the company's shares effective 8 January 2025.」
The Company acquired 滋賀県製薬 for 88.3% of the voting rights and a cash consideration of ¥9.5 billion, recording net sales of ¥5,054 million and profit for the year of ¥620 million attributable to owners of the parent from the acquisition date onward. In addition, it disclosed an agreement to acquire 60% of the voting rights in Vietnam-based USM Healthcare for approximately ¥5.8 billion, scheduled for March 2026 after the filing, thereby expanding its medical device production and sales base in Asia. - FY2025-H1AdvancedAnnual report
「At a meeting of the Board of Directors held on 20 December 2024, the Company resolved to acquire the shares of 滋賀県製薬株式会社 (滋賀県製薬) and make it a subsidiary. It acquired the company's shares effective 8 January 2025.」
Effective 8 January 2025, the Company acquired shares in 滋賀県製薬, obtaining 88.3% of the voting rights and incorporating its pharmaceutical manufacturing and manufacturing-and-marketing business for a cash consideration of ¥9.5 billion. It recorded net sales of ¥2,525 million and interim profit of ¥480 million attributable to owners of the parent from the acquisition date onward. - FY2024AdvancedAnnual report
「Acquired Cathtek, LLC through Eimo Technologies, Inc. and Nissha Eimo Acquisition Corp.」
Effective 1 October 2024, the Company acquired 85% of Cathtek's voting rights, incorporating through M&A its production and sales of injection-molded products for medical devices, quality management systems, and customer base. - FY2024-H1AdvancedAnnual report
「Results of the acquired company from the acquisition date onward included in the summarized interim consolidated statement of income: Net sales 1,677; Interim profit attributable to owners of the parent 353」
For Isometric, acquired in March 2024, the Company recorded net sales of ¥1,677 million and interim profit of ¥353 million attributable to owners of the parent from the acquisition date onward, with the post-acquisition contribution to results expanding in the interim period. - FY2024-Q1AdvancedAnnual report
「At a meeting of the Board of Directors held on 4 December 2023, the Company resolved to acquire an equity interest in Isometric Intermediate LLC (commonly known as Isometric Micro Molding) through its consolidated subsidiaries Graphic Controls Acquisition Corp. and Nissha Medical Technologies (Wisconsin), LLC (NMT LLC), both in the Medical Technology business, and to make Isometric Intermediate LLC and its group companies (collectively, Isometric) subsidiaries. The acquisition of the equity interest was completed effective 1 March 2024.」
The Company reconfirmed the completion of the acquisition of the equity interest in Isometric and its inclusion in the scope of consolidation from the first quarter. It disclosed an acquired voting rights ratio of 75.53% and transfer consideration of ¥10,218 million. It also recorded net sales of ¥396 million and quarterly profit of ¥70 million attributable to owners of the parent from the acquisition date onward. - FY2023AdvancedAnnual report
「At a meeting of the Board of Directors held on 4 December 2023, the Company resolved to acquire an equity interest in Isometric Intermediate LLC (commonly known as Isometric Micro Molding) through its consolidated subsidiaries Graphic Controls Acquisition Corp. and Nissha Medical Technologies (Wisconsin), LLC (NMT LLC), both in the Medical Technology business, and to make Isometric Intermediate LLC and its group companies (collectively, Isometric) subsidiaries. The acquisition of the equity interest was completed effective 1 March 2024.」
The acquisition of the equity interest in Isometric was completed effective 1 March 2024, after the filing. The acquired voting rights ratio was 75.53%, and the acquisition consideration, including earn-out payments, was up to US$70,192 thousand. The Company is incorporating Isometric's manufacturing and sales capabilities for small, precision components used in medical devices through M&A. - FY2023-Q3AdvancedAnnual report
「Cash used in investing activities totaled ¥4,930 million, down 3.6% year on year. This was mainly due to expenditures of ¥2,489 million for the acquisition of property, plant and equipment and ¥3,012 million for the acquisition of shares in affiliates, among other items.」
During the nine months ended [the third quarter], the Company spent ¥3,012 million on the acquisition of shares in affiliates, indicating progress in business expansion through M&A and investment. - FY2023-Q2AdvancedAnnual report
「Cash used in investing activities totaled ¥4,144 million, up 24.8% year on year. This was mainly due to expenditures of ¥1,836 million for the acquisition of property, plant and equipment and ¥2,970 million for the acquisition of shares in affiliates, among other items.」
The Company spent ¥2,970 million on the acquisition of shares in affiliates, while investments accounted for using the equity method under non-current assets also increased by ¥3,173 million, indicating progress in business expansion through M&A and investment. No target company names or details on completion of the acquisitions are provided. - FY2023-Q1AdvancedAnnual report
「Payments for the acquisition of shares in affiliates 413 Advance payments related to the acquisition of shares in affiliates 2,197」
The Company spent ¥413 million on the acquisition of shares in affiliates and paid ¥2,197 million in advance payments related to acquisitions, indicating tangible progress in funding business expansion through M&A and investment. No target company names or details on completion of the acquisitions are provided. - FY2020AdvancedAnnual report
「Through the end of the period, the Group expanded its business bases and product lineup through an active M&A strategy in the medical device and sustainable materials markets.」
The Company expanded its priority markets through M&A over the full year, including expanding Eurofoil's European bases and product lineup for metallized paper and expanding production capacity in the medical device business through the acquisition of Olympus's Norwalk plant. - FY2020-Q3AdvancedAnnual report
「Through Nissha Medical Technologies (Ohio), Inc., a consolidated subsidiary of its Medical Technology business, the Company acquired the Norwalk plant of Olympus Surgical Technologies America, effective 2 November 2020.」
As an M&A transaction in the Medical Technology business, the Company acquired the Norwalk plant of Olympus Surgical Technologies America. - FY2020-Q2AdvancedAnnual report
「Like ARM, Eurofoil is a manufacturer of metallized paper. In addition to sales channels and production capacity for food and tobacco packaging in Europe, it has proprietary processing technologies, including coating and lamination, that complement ARM's capabilities. Through this acquisition, ARM will expand its share of the European metallized paper market and accelerate the development of new products using Eurofoil's processing technologies.」
As a contribution from Eurofoil following the acquisition, the Company recorded ¥2,801 million in net sales and ¥58 million in quarterly profit attributable to owners of the parent from the acquisition date onward, while continuing to incorporate its European sales channels, production capacity, and processing technologies. - FY2020-Q1AdvancedAnnual report
「Like ARM, Eurofoil is a manufacturer of metallized paper. In addition to sales channels and production capacity for food and tobacco packaging in Europe, it has proprietary processing technologies, including coating and lamination, that complement ARM's capabilities. Through this acquisition, ARM will expand its share of the European metallized paper market and accelerate the development of new products using Eurofoil's processing technologies.」
On 31 January 2020, the Company acquired 100% of Eurofoil Paper Coating GmbH for a cash consideration of ¥1,251 million and contingent consideration of ¥180 million. By incorporating its European sales channels and production capacity and its processing technologies, the acquisition began contributing ¥1,133 million in net sales and ¥2 million in profit for the quarter attributable to owners of the parent from the acquisition date onward. - FY2019-Q2AdvancedAnnual report
「The voting rights ratio represented by the additionally acquired shares was 2.87%. To further enhance the corporate value of the Group, the Company acquired the shares held by non-controlling shareholders and made the company a wholly owned subsidiary.」
On 28 June 2019, the Company additionally acquired shares in Graphic Controls Holdings, Inc., representing 2.87% of the voting rights, and made it a wholly owned subsidiary. The acquisition cost was ¥770 million. - FY2018AdvancedAnnual report
「The business scale expanded as the results of 3 companies acquired during the fiscal year were consolidated. At the same time, one-time costs, including acquisition-related expenses and site integration costs, were incurred.」
The Medical Technology business expanded through the consolidation of 3 companies acquired in fiscal 2018. - FY2018-Q3AdvancedAnnual report
「During the nine months ended [the third quarter], product demand in the Device business, which had been sluggish in the first half, began to expand in the second half. In the Medical Technology business, the growth strategy through acquisitions began contributing to results.」
The disclosure describes specific progress in the Medical Technology business's acquisition-led growth strategy, namely the start of its contribution to results. - FY2018-Q2AdvancedAnnual report
「Through the acquisition of Heart Sync's assets, the Medical Technology business will expand its product lineup of defibrillation electrodes and gain sales channels. By acquiring tangible and intangible assets, including Heart Sync's highly competitive development and design capabilities, it aims to create synergies with the Graphic Controls group. Business combination date: 18 May 2018. Acquisition cost: ¥1,340 million. Business combination date: 25 June 2018. Acquisition cost: ¥1,536 million.」
The Company acquired the business of Heart Sync and equity interests in Sequel Special Products and RSS Design. It is expanding its product and sales channels for defibrillation electrodes and contract manufacturing for minimally invasive medicine and orthopedics. - FY2018-Q1Cited as achievedAnnual report
「Under the Fifth Mid-Term Management Plan, which ended in fiscal 2017, the Company secured new large orders through product development and capital investment targeting its core consumer electronics (IT) market. It also expanded its business bases in the automotive market and entered new businesses in the medical device and high-performance packaging materials fields through an active M&A strategy.」
The large orders secured, expansion of automotive bases, and entry into the medical device and high-performance packaging materials fields achieved under the Fifth Mid-Term Management Plan are cited as past accomplishments. - FY2017-Q3AdvancedAnnual report
「Life Innovation is a new segment focused primarily on the medical device manufacturer Graphic Controls group. It aims to contribute to healthy and prosperous lives by providing high-quality, high-value-added products in the medical device and related fields. Its main products include disposable electrodes and surgical instruments for medical institutions. It currently produces and sells products under its own brands in Western markets, while also undertaking contract manufacturing for major medical device manufacturers. During the six months ended [the second quarter], product demand remained firm, particularly in the core contract manufacturing business. As a result, consolidated net sales for the six months ended [the second quarter] were ¥8,996 million, and segment profit (operating profit) was ¥216 million.」
In the Life Innovation business built around Graphic Controls, demand remained firm, mainly in contract manufacturing, generating cumulative net sales of ¥8,996 million and segment profit of ¥216 million. The business contribution following the acquisition is progressing in measurable terms. - FY2017-Q2AdvancedAnnual report
「During the three-month period ended 30 June, results were broadly in line with expectations. The business expanded in scale, partly due to contributions from the medical device field, while the core Devices business incurred upfront costs related to preparations for mass production of a large order. As a result, consolidated sales for the three-month period ended 30 June were ¥4.461 billion, and segment profit was ¥125 million.」
The Life Innovation business, built around Graphic Controls, benefited from growing contributions from the medical device field and recorded quarterly sales of ¥4.461 billion and segment profit of ¥125 million. - FY2017AdvancedAnnual report
「Through the end of the period, the Company worked to restructure and optimize its business portfolio. It secured large orders through product development and capital investment targeting its core consumer electronics (IT) market, expanded its business bases in the automotive market through an active M&A strategy, and entered new businesses in the medical device and high-performance packaging materials fields.」
The Company expanded its automotive business bases and entered the medical device and high-performance packaging materials fields. In October 2017, it also acquired Financière Intégral SAS and its subsidiaries, continuing to expand its business scope through M&A. - FY2017RestatedAnnual report
「Through this acquisition, the Group added medical device products and markets to its business portfolio and acquired global sales channels. Going forward, it will use the Graphic Controls group as a platform to expand its business in the medical market and build a balanced business foundation alongside its existing consumer electronics operations.」
The Group has positioned the acquisitions of Graphic Controls, Schuster and Back Stickers as M&A under the Fifth Medium-Term Management Plan and has reaffirmed its expansion into medical devices, automotive interiors and other fields. - FY2016-Q4AdvancedAnnual report
「By including Graphic Controls Holdings, Inc. and its group companies in the scope of consolidation during the three-month period ended 31 December, the Group established Life Innovation as a new reporting segment for the group, which operates in the medical market. Sales contributions to the Group began in the third quarter, but there was no contribution to profit because acquisition-related expenses were recorded. As a result, consolidated sales for the nine-month period ended 31 December were ¥1.277 billion, and the segment loss (operating loss) was ¥565 million.」
Following the Graphic Controls acquisition, the Group reported the Life Innovation business as a new segment, which began contributing sales of ¥1.277 billion. However, acquisition-related expenses prevented a contribution to profit. - FY2016-Q3AdvancedAnnual report
「Following the AR Metallizing group acquisition the previous year, the Group's M&A strategy under the Fifth Medium-Term Management Plan progressed as planned, including the acquisition and conversion into subsidiaries of the US-headquartered medical device manufacturer Graphic Controls group on 2 September 2016, and the German molding and decorative film manufacturers Schuster and Back Stickers groups in the automotive segment of Industrial Materials on 31 October.」
The Group disclosed that the acquisition and conversion into a subsidiary of the Graphic Controls group had been completed, and that the Schuster and Back Stickers groups in the automotive field had also been converted into subsidiaries. - FY2016-Q2AdvancedAnnual report
「At a meeting of the Company's Board of Directors held on 5 August 2016, the Company resolved to acquire shares in Graphic Controls Holdings, Inc., a holding company, from WestView Capital Partners II, L.P. and others through its consolidated subsidiary Nissha Medical International, Inc., thereby making Graphic Controls Acquisition Corp. and its group companies subsidiaries. The Company entered into a share transfer agreement on the same date. Scheduled acquisition date: late August 2016; acquisition price: US$135 million; ownership interest after acquisition: 97.1%.」
The acquisition of the medical-device manufacturer Graphic Controls Group progressed through Board approval and execution of a share transfer agreement. The acquisition had not yet closed, and the expected timing was disclosed. - FY2016First statedAnnual report
「In August 2015, the Company's Industrial Materials business acquired the AR Metallizing Group, the global leader in metallized paper. This brought metallized paper, a printing-related material, into the product portfolio and added sales territories in global markets for beverages, food products and daily-use goods, where stable growth is expected. Málaga holds a 45% share of the metallized paper market in South America and has diverse production technologies, including film metallization and lamination.」
The acquisitions of the AR Metallizing Group and Málaga added the metallized paper business, production capacity in South America and related sales channels.